These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
64. The psychopharmacological treatment of nonmajor mood disorders. Yonkers KA; Clark RH; Trivedi MH Mod Probl Pharmacopsychiatry; 1997; 25():146-66. PubMed ID: 9344374 [No Abstract] [Full Text] [Related]
65. Qualms about balms: perspectives on antidepressants. Greenberg RP J Nerv Ment Dis; 2001 May; 189(5):296-8. PubMed ID: 11379972 [No Abstract] [Full Text] [Related]
66. Neuropsychopharmacologic treatment of depression and other neuropsychiatric disorders in HIV-infected individuals. Repetto MJ; Evans DL; Cruess DG; Gettes DR; Douglas SD; Petitto JM CNS Spectr; 2003 Jan; 8(1):59-63. PubMed ID: 12627050 [TBL] [Abstract][Full Text] [Related]
75. Reboxetine in depression. NICE guidance differs, so where next? Krishnadas R BMJ; 2010 Nov; 341():c6484. PubMed ID: 21081613 [No Abstract] [Full Text] [Related]
76. Keeping 'em honest: the current crisis of confidence in antidepressants. Teboul E J Clin Psychiatry; 2011 Jul; 72(7):1015; author reply 1015-6. PubMed ID: 21824461 [No Abstract] [Full Text] [Related]
77. Placebo response in depression: bane of research, boon to therapy. Andrews G Br J Psychiatry; 2001 Mar; 178():192-4. PubMed ID: 11230026 [No Abstract] [Full Text] [Related]
78. Commentary. What should doctors do in the face of negative evidence? Eisenberg L J Nerv Ment Dis; 1996 Feb; 184(2):103-5. PubMed ID: 8596105 [No Abstract] [Full Text] [Related]
79. Pharmacological management of depression in patients with cancer: practical considerations. Torta RG; Ieraci V Drugs; 2013 Jul; 73(11):1131-45. PubMed ID: 23839658 [TBL] [Abstract][Full Text] [Related]
80. The role of the patient in treatment decisions. Linden M Mod Probl Pharmacopsychiatry; 1997; 25():192-202. PubMed ID: 9344377 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]